Home › Chronic Lymphocytic Leukemia › Alabama
Pag-aaral pangklinika para sa Chronic Lymphocytic Leukemia sa Alabama
7 pag-aaral para sa Chronic Lymphocytic Leukemia ang naghahanap ng mga kalahok sa mga site sa Alabama.
Mga Lungsod sa Alabama
Opisyal na teksto ng pag-aaral (English)
HPC Offered for PRESERVE Expansion
- University of Alabama, Birmingham, Birmingham
Nagre-recruitObservasyonal na pag-aaral
Edad 12 hanggang 80 · Lahat ng kasarian · Na-update Nob 6, 2026 · NCT07145411A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Mitchell Cancer Institute, Mobile
Nagre-recruitPhase 4
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT07218341Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- University of Alabama at Birmingham Cancer Center, Birmingham
Nagre-recruitPhase 3
Edad 65 pataas · Lahat ng kasarian · Na-update Nob 3, 2026 · NCT07321652A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- USA Mitchell Cancer Institute ( Site 0014), Mobile
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 13, 2026 · NCT06136559A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- University of Alabama At Birmingham Hospital, Birmingham
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT05006716A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- University of Alabama At Birmingham Hospital, Birmingham
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT06973187Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- O'Neal Comprehensive Cancer Center, University of Alabama, Birmingham
Nagre-recruitPhase 1/2
Edad 12 pataas · Lahat ng kasarian · Na-update Set 3, 2026 · NCT04588922Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.